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Neuromyelitis optica (NMO) shows a marked female prepon-
derance and may affect patients in childbearing age, often suf-
fering from disabling relapses by inflammation of the optic 
nerve and the spinal cord.1 According to retrospective case 
studies, patients with NMO are prone to relapses shortly after 
delivery,2,3 similar to multiple sclerosis (MS).4 Rituximab is a 
chimeric monoclonal anti-CD20 antibody shown to prevent 
NMO relapses in independent retrospective case series and 
prospective long-term studies.5,6 Recently, the clinical course 
of NMO in a pregnant woman who received rituximab shortly 
before conception and experienced two relapses 10 days and 
two months after delivery has been described.7 Here, we 
report the case of an NMO patient who became pregnant fol-
lowing low-dose rituximab and remained stable by early post-
partum rituximab treatment.
Case report
The previously healthy 18-year-old woman had developed 
a subacute Brown-Séquard syndrome in October 2008 after 
human papillomavirus- and Neisseria meningitidis vacci-
nations as previously reported (case no. 1 in the report by 
Menge et al.8). Three months later, she suffered from 
severe left-sided optic neuritis (ON), spastic paraparesis 
and bladder dysfunction, and NMO was diagnosed (anti-
aquaporin 4 (AQP4) antibody ratio: 48.5, measured by 
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Neuromyelitis optica (NMO) predominantly affects women, some in childbearing age, and requires early therapeutic 
intervention to prevent disabling relapses. We report an anti-AQP4 antibody-seropositive patient who became pregnant 
seven months after low-dose (100 mg) rituximab application. Pregnancy showed no complications, and low-dose 
rituximab restarted two days after delivery resulted in neurological stability for 24 months. Remarkably, her otherwise 
healthy newborn presented with anti-AQP4 antibody and reduced B lymphocyte counts in umbilical cord blood, which 
normalized three months later. Confirming and extending previous reports, our case suggests that low-dose rituximab 
might be compatible with pregnancy and prevent rebound NMO disease activity postpartum.
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radioimmunoprecipitation; Figure). After relapse therapy 
with high-dose steroids and plasma exchange, rituximab 
was initiated (1000 mg twice within two weeks) and the 
patient partially improved. Shortly after, she became inad-
vertently pregnant for the first time and medically indicated 
termination was performed at 19 years of age (in June 
2009). Eight months later, she developed another severe 
left-sided ON, leading to blindness despite therapy with 
high-dose steroids. At this time (February 2010), CD19+ B 
cell count was at 5% (normal range, 5–24). In light of grow-
ing experiences with adaptation of rituximab therapy regi-
men,9 our patient was treated with low-dose rituximab (single 
application of 100 mg) leading to persisting B cell depletion 
and anti-AQP4 antibody disappearance until the age of 20 
years (August 2010). One month later, seven months after 
the last rituximab infusion, the patient became pregnant 
again (CD19+ B cell count: 3%). During pregnancy, no 
relapses occurred, but anti-AQP4 antibody reappeared (now 
measured by cell-based immunofluorescence (CBA)), while 
CD19+ B cells further decreased (10/2010: 3%; 01/2011: 
2%; 06/2011: 1%, Figure). After 38 weeks of pregnancy, a 
healthy, normally developed male child was delivered by 
caesarean section (length 50 cm, weight 3220 g). Remarkably, 
analysis of the newborn’s umbilical cord blood (Figure, 
inset) showed decreased CD19+ B cells (2%, normal range, 
5–24) and increased anti-AQP4 antibody titers (1:100; 
CBA); however, the baby did not show any specific neuro-
logical deficits. The mother presented reduced B cell counts 
(1%) and reduced immunoglobulin G (IgG) serum levels 
(608 mg/dl; normal range, 700–1600), but still increased 
anti-AQP4 antibody titers (1:100, CBA), comparable to her 
offspring. In light of these findings and the patient’s disa-
bling disease course prior to pregnancy, she was treated 
again with rituximab (100 mg) two days after delivery. Nine 
days thereafter, the patient presented with fever, lower 
abdominal pain and fatigue. Endometritis or cystitis was sus-
pected and successfully treated with metronidazol, sultami-
cillin and oxytocin. Since delivery, no NMO relapses 
occurred for the following 24 months on low-dose rituximab 
(100 mg) treatments every five to seven months, while anti-
AQP4 antibody titers persisted (Figure). Anti-AQP4 anti-
body testing of the baby turned negative and CD19+ B cells 
normalized at three and six months after birth. Except for a 
mild rhinitis and conjunctivitis at the age of one month, the 
child developed normally, and no neurological or other 
abnormalities occurred until the current age of 24 months.
Comment
Our case confirms and extends recent observations on 
NMO, pregnancy and rituximab: Recent studies indicate 
that NMO patients are prone to relapses during the first and 
second trimester after delivery,2,3 similar to patients with 
relapsing MS.4 The underlying mechanisms, however, are 
Figure. Disease course, laboratory parameters and therapy of NMO patient. Shown are relapses (diamonds), acute and long-term 
treatments (intravenously applied high-dose steroid therapy, 1000 mg per day for three to five days; plasma exchange, rituximab), 
and the two pregnancies of the NMO patient over a follow-up period of 52 months. No relapses occurred during pregnancy and 
postpartum on a low-dose rituximab treatment seven months before pregnancy and two days after delivery. Moreover, anti-AQP4 
antibody ratios or titers, CD19+ B cell counts, CD4+ T cell counts and percentages and IgG serum values are presented. Two 
different anti-AQP4 antibody detection assays were applied in the mother (radioimmunoprecipitation assay until August 2010; cell-
based immunofluorescence assay thereafter). (Inset) Laboratory parameters of newborn. Reduced B cell counts and increased anti-
AQP4-antibodies in the umbilical cord blood of the child normalized within three months. Anti-AQP4 antibodies were determined 
by cell-based immunofluorescence assay (see above).
NMO: neuromyelitis optica; AQP4: aquaporin 4; IgG: immunoglobulin G.
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unclear. It has been suggested that withdrawal of preg-
nancy-related immunological tolerance mechanisms, medi-
ated by regulatory T cells,10 induce an immunological and 
clinical rebound effect. Considering the severity of NMO 
relapses, preventive therapy in the postpartum phase may 
therefore prove justified and our case suggests a rationale 
for such an intervention early after delivery. Our patient 
had received rituximab seven months before pregnancy and 
two days after delivery at a dose of 100 mg and remained 
stable throughout these periods. Remarkably, the newborn 
had reduced B lymphocyte levels in the umbilical blood, 
returning to normal after three months, indicating a sus-
tained but transient biological effect of even low-dose 
rituximab on the infant’s immune system (Figure). Except 
for a suspected abdominal infection requiring antibiotics 
nine days after caesarean delivery, no safety signals were 
detected for the mother. These findings support previous 
experiences with an NMO patient with inadvertent concep-
tion one week after application of high-dose rituximab 
(1000 mg twice within two weeks).7 In that report, the child 
developed normally during follow-up for 15 months after 
birth. The mother was clinically stable during pregnancy, 
but had not been treated upon delivery and experienced two 
severe relapses 10 days and two months thereafter.7
In our patient, the correlation between anti-AQP4 anti-
body titers and clinical disease activity, as previously 
observed,11 as well as the relation between rituximab 
administration and anti-AQP4 antibody, remained ambigu-
ous. Rituximab may disrupt T-B lymphocyte interactions, 
which is beneficial in MS and NMO, while we were not 
able to establish a solid correlation between anti-AQP4 
antibody titers, clinical relapses and drug application. Thus, 
our data corroborate recent suggestions for studies on bio-
marker validation in NMO.12
Finally, we here show that anti-AQP4 antibody can be 
transferred from the mother to the child but may not have 
harmful effects in the latter. The full-term male child 
showed no neurological or other abnormalities during 24 
months of follow-up, in line with earlier reports on off-
spring of NMO patients.2,3 As the baby was seronegative 
for anti-AQP4 antibody three months after delivery, we 
assume a passive transfer from the seropositive mother to 
the child without any obvious impact, similar to the passive 
antibody transfer to newborns in myasthenia gravis.13
In conclusion, our case suggests that anti-AQP4 anti-
body may pass the blood-placenta barrier without causing 
neurological deficits in the newborn child, and that early 
maternal postpartum rituximab therapy may be an option to 
prevent rebound NMO disease activity after delivery.
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